0.83 is Celgene Corp’s (NASDAQ:CELG) Big Money Sentiment

May 17, 2018 - By Tamara Reed

Celgene Corporation (NASDAQ:CELG) Corporate Logo

Positions for Celgene Corp (NASDAQ:CELG)

In 2017 Q4 Celgene Corp (NASDAQ:CELG) big money sentiment decreased to 0.83, revealed SEC filings. That’s down -0.34, from 2017Q3’s 1.17. 529 active investment managers increased or started new holdings, while 634 cut down and sold stakes in Celgene Corp so the sentiment has dropped. Funds own 561.38 million shares, down from 603.99 million shares in 2017Q3. Funds holding Celgene Corp in top 10 decreased from 119 to 38 for a decrease of 81. 156 Investors Sold All; 478 Reduced Holdings; 411 increased stakes while 118 active investment managers bought stakes.

Biggest Celgene Corp Investors

Birchview Capital Lp owns 744,051 shares in Celgene Corp as of 2017 Q4. Celgene Corp’s shareholder Oaktop Capital Management Ii L.P. owns 2.11 million shares as of 2017 Q4. Selkirk Management Llc reported 260,000 shares. The Switzerland-based fund Bb Biotech Ag have invested about 10.06% of the investment professional’s stock portfolio in Celgene Corp. The United Kingdom-based fund Edinburgh Partners Ltd looks positive on Celgene Corp, possessing 315,906 shares.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide.The firm is valued at $59.09 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.The P/E ratio is 22.35. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Ticker’s shares touched $81.36 during the last trading session after 0.76% change.Celgene Corporation has volume of 6.04 million shares. Since May 17, 2017 CELG has declined 31.28% and is downtrending. The stock underperformed the S&P500 by 42.83%.

Celgene Corporation (NASDAQ:CELG) is expected to announce earnings on July, 26., as reported by Faxor. Analysts expect change of 11.31 % or $0.19 from previous year’s $1.68 EPS compared to current’s $1.87 EPS. If $1.87 is reported, CELG’s profit will reach $1.36B for 10.88 P/E. Analysts at Wall Street see Celgene Corporation’s 16.15 % EPS growth compared to $1.61 EPS for previous quarter.

Howe & Rusling Incorporated accumulated 0.38% or 20,125 shs. Arrow Fincl stated it has 0.54% in Celgene Corporation (NASDAQ:CELG). Ameriprise Fincl Incorporated stated it has 0.47% of its capital in Celgene Corporation (NASDAQ:CELG). Piedmont Advsr Limited Liability Company stated it has 0.35% of its capital in Celgene Corporation (NASDAQ:CELG). Vantage Inv Lc stated it has 0% in Celgene Corporation (NASDAQ:CELG). Tarbox Family Office Inc accumulated 1,314 shs. Cape Cod Five Cents National Bank, a Massachusetts-based fund reported 2,525 shs. State Street holds 32.18 million shs or 0.27% of its capital. Brown Cap Management Ltd owns 28,129 shs. Mcf Llc reported 95 shs. Winslow Evans And Crocker Incorporated owns 11,780 shs or 0.4% of their US capital. Hennessy has 5,510 shs. Citizens Northern stated it has 1.21% in Celgene Corporation (NASDAQ:CELG). Banced Corporation holds 5,247 shs or 0.91% of its capital. Legal & General Public Ltd Company reported 3.74M shs.

Celgene Corporation registered $3.58 million net activity with 1 buy and 3 selling transactions since February 8, 2018. LOUGHLIN JAMES J had sold 9,250 shs worth $851,093 on Monday, March 12. 13,370 Celgene Corporation (NASDAQ:CELG) shs with value of $1.26M were sold by MARIO ERNEST. Alles Mark J bought $299,594 worth of stock or 3,260 shs.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

A total of 20 analysts rate Celgene (NASDAQ:CELG) as follows: 13 “Buy”, 7 “Hold” and 0 “Sell”. Тherefore 65% are bullish. The firm has $152.0 highest and $90 lowest target. The avg target $122 is 49.95% above the last ($81.36) price. (NASDAQ:CELG) has 35 ratings reports on 17 May 2018 according to StockzIntelligence. The company rating was maintained by Leerink Swann on Monday, May 7. On Thursday, December 21 the rating was maintained by Guggenheim with “Buy”. On Monday, May 7 the firm has “Equal-Weight” rating by Morgan Stanley given. On Wednesday, February 28 BMO Capital Markets maintained the shares of CELG in report with “Outperform” rating. On Monday, January 8 the company was maintained by SunTrust. On Monday, May 7 the firm has “Outperform” rating by RBC Capital Markets given. In Monday, February 5 report Mizuho maintained it with “Buy” rating and $128.0 target. The stock rating was maintained by Piper Jaffray with “Hold” on Thursday, January 25. The stock rating was upgraded by Atlantic Securities to “Overweight” on Friday, December 8. In Thursday, January 25 report SunTrust maintained it with “Buy” rating and $139.0 target.

For more Celgene Corporation (NASDAQ:CELG) news brought out recently go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Fool.com or Streetinsider.com. The titles are as follows: “My 2 Cents On The Ozanimod Saga” brought out on May 15, 2018, “Celgene And Otezla Are Cracking” on May 14, 2018, “Celgene: Bold Pursuits In Science With 24.66% Discount” with a publish date: April 23, 2018, “Celgene Starts the Year With a Bang” and the last “Celgene (CELG) to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at ASCO” with publication date: May 16, 2018.

Celgene Corporation (NASDAQ:CELG) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: